ArticleIJU case reports2026
A Case of a Durable Partial Response to Late-Line Axitinib Following Prior Use of Tyrosine Kinase Inhibitors in Metastatic Papillary Renal Cell Carcinoma.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metastatic papillary renal cell carcinoma (PRCC) is associated with a poor prognosis. Many patients with PRCC respond to first- and second-line systemic chemotherapy treatments; however, few respond to late-sequence treatment. We describe a case of a long-term response to fourth-line axitinib after the use of tyrosine kinase inhibitor therapy for metastatic papillary renal cell carcinoma. Case Presentation: A 37-year-old male presented with hematuria and left back pain. Following systemic examination, he was diagnosed with left renal cell carcinoma cT3aN0M1. He underwent left radical nephrectomy. The pathological diagnosis was PRCC type 2. After using sunitinib, cabozantinib, and nivolumab, axitinib was selected as fourth-line systemic therapy, resulting in a reduction in multiple liver metastases and 15 months of response. Conclusion: Late-sequence treatment with axitinib following prior use of tyrosine kinase inhibitor therapy resulted in a long-term response in a patient with metastatic papillary renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.